Payment overview · 2025
General Payments
$13,873.48
231 reported records · 30 companies
Healthcare provider profile · identity verified
Dan Pham, MD
Allopathic & Osteopathic Physicians|Hospitalist · FALLS CHURCH, VA · NPI 1518313659
Verified facts
What the public records show
CMS Open Payments records show Dan Pham, MD received $13,873.48 in general payments during 2025 across 231 reported records.
Amgen Inc. accounted for 47.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 50 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Paxlovid, Prolia, Rybelsus, Vemlidy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 539 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 393 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Vemlidy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 393 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $6,539.16 | 47.1% | 29 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $2,847.54 | 20.5% | 20 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $551.36 | 4.0% | 14 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $409.04 | 3.0% | 13 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $406.77 | 2.9% | 18 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $383.20 | 2.8% | 28 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $344.63 | 2.5% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $327.37 | 2.4% | 8 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $213.14 | 1.5% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $198.29 | 1.4% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $191.90 | 1.4% | 17 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $178.78 | 1.3% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $162.16 | 1.2% | 7 | 2025 |
| Tempus AI, Inc | Unresolved — no canonical attribution shown | $141.66 | 1.0% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $127.09 | 0.9% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $125.73 | 0.9% | 7 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $119.16 | 0.9% | 6 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $114.29 | 0.8% | 7 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $105.54 | 0.8% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $64.72 | 0.5% | 3 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $52.18 | 0.4% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $48.16 | 0.3% | 2 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.37 | 0.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.99 | 0.3% | 2 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $30.16 | 0.2% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $24.88 | 0.2% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $23.84 | 0.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.67 | 0.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $16.36 | 0.1% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $15.34 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,850.00 | 6 |
| Food and Beverage | $6,023.48 | 225 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $6,279.40 | 22 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $2,511.51 | 10 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $406.77 | 18 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $387.30 | 16 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $383.20 | 28 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $327.37 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $304.57 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $274.06 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $246.79 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $236.51 | 5 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $198.29 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $178.78 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $162.20 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $162.16 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $149.16 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $144.38 | 7 | 2025 |
Source payment records
|
|||||
| XT CDX Normalized: xt cdx |
Device | Tempus AI, Inc | $141.66 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $127.09 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $125.73 | 7 | 2025 |
Source payment records
|
|||||
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $123.07 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $119.16 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $118.87 | 10 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $118.87 | 10 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $118.87 | 10 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $115.15 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $114.29 | 7 | 2025 |
Source payment records
|
|||||
| EUFLEXXA Normalized: euflexxa |
Device | Ferring Pharmaceuticals Inc. | $105.54 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $101.23 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $98.77 | 6 | 2025 |
Source payment records
|
|||||
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $97.99 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $73.03 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $57.85 | 6 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $54.64 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $48.16 | 2 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $45.37 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $45.20 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $44.99 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $44.84 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $42.13 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $31.08 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $30.16 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $25.37 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 66 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 539 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 46 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 393 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 253 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 28 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 17 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 29 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 144 | exact normalized | Medicare Part D |
| Vemlidy vemlidy |
2025 | Vemlidy | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
29 | 20 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
74 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
539 | 112 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
253 | 46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
393 | 79 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
83 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
393 | 79 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
144 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
46 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1163 | 394 |
| Amlodipine Besylate | Amlodipine Besylate | 830 | 264 |
| Losartan Potassium | Losartan Potassium | 748 | 254 |
| Metformin Hcl | Metformin Hcl | 655 | 204 |
| Atorvastatin Calcium | Atorvastatin Calcium | 604 | 186 |
| Farxiga | Dapagliflozin Propanediol | 539 | 112 |
| Meloxicam | Meloxicam | 514 | 224 |
| Prednisone | Prednisone | 476 | 296 |
| Fluticasone Propionate | Fluticasone Propionate | 411 | 182 |
| Diclofenac Sodium | Diclofenac Sodium | 408 | 171 |
| Jardiance | Empagliflozin | 393 | 79 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 338 | 152 |
| Gabapentin | Gabapentin | 308 | 123 |
| Celecoxib | Celecoxib | 291 | 103 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 288 | 143 |
| Azithromycin | Azithromycin | 285 | 187 |
| Metoprolol Succinate | Metoprolol Succinate | 281 | 85 |
| Lisinopril | Lisinopril | 275 | 92 |
| Tamsulosin Hcl | Tamsulosin Hcl | 259 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 255 | 115 |
| Kerendia | Finerenone | 253 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 228 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 224 | 109 |
| Simvastatin | Simvastatin | 222 | 68 |
| Meclizine Hcl | Meclizine Hcl | 217 | 105 |
| Omeprazole | Omeprazole | 201 | 72 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 188 | 67 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 182 | 52 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 180 | 59 |
| Lidocaine | Lidocaine | 174 | 62 |
| Alprazolam | Alprazolam | 170 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 169 | 53 |
| Nifedipine Er | Nifedipine | 162 | 50 |
| Furosemide | Furosemide | 160 | 60 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 156 | 95 |
| Rybelsus | Semaglutide | 144 | 29 |
| Glimepiride | Glimepiride | 142 | 41 |
| Montelukast Sodium | Montelukast Sodium | 130 | 51 |
| Megestrol Acetate | Megestrol Acetate | 124 | 56 |
| Allopurinol | Allopurinol | 121 | 50 |
| Clonidine Hcl | Clonidine Hcl | 121 | 54 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 120 | 44 |
| Methocarbamol | Methocarbamol | 118 | 68 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 116 | 40 |
| Trazodone Hcl | Trazodone Hcl | 111 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 34 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 103 | 26 |
| Alendronate Sodium | Alendronate Sodium | 101 | 34 |
| Colchicine | Colchicine | 98 | 34 |
| Finasteride | Finasteride | 96 | 40 |
| Amoxicillin | Amoxicillin | 94 | 60 |
| Donepezil Hcl | Donepezil Hcl | 92 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 45 |
| Glipizide | Glipizide | 91 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 91 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 31 |
| Ketoconazole | Ketoconazole | 87 | 29 |
| Carvedilol | Carvedilol | 86 | 30 |
| Vemlidy | Tenofovir Alafenamide | 83 | 17 |
| Fluocinonide | Fluocinonide | 81 | 42 |
| Loperamide | Loperamide Hcl | 78 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 23 |
| Myrbetriq | Mirabegron | 74 | 28 |
| Mirtazapine | Mirtazapine | 73 | 15 |
| Tramadol Hcl | Tramadol Hcl | 71 | 27 |
| Famotidine | Famotidine | 70 | 29 |
| Januvia | Sitagliptin Phosphate | 69 | 18 |
| Eliquis | Apixaban | 66 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 65 | 26 |
| Hydrocortisone | Hydrocortisone | 62 | 36 |
| Fenofibrate | Fenofibrate | 60 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 57 | 20 |
| Ibuprofen | Ibuprofen | 57 | 33 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 57 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 55 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 17 |
| Vascepa | Icosapent Ethyl | 53 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 52 | 19 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 50 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 35 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | 19 |
| Gemtesa | Vibegron | 46 | 23 |
| Potassium Chloride | Potassium Chloride | 45 | 17 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 45 | 14 |
| Diazepam | Diazepam | 43 | suppressed |
| Entecavir | Entecavir | 40 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 27 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 39 | 11 |
| Halobetasol Propionate | Halobetasol Propionate | 39 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 12 |
| Glipizide Er | Glipizide | 38 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Valsartan | Valsartan | 37 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 36 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 35 | 24 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 35 | 26 |
| Sucralfate | Sucralfate | 34 | 13 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 32 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 32 | 11 |
| Procto-Med Hc | Hydrocortisone | 32 | 14 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Atenolol | Atenolol | 31 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 31 | 14 |
| Metformin Hcl Er | Metformin Hcl | 30 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | 13 |
| Pregabalin | Pregabalin | 29 | 11 |
| Prolia | Denosumab | 29 | 20 |
| Linzess | Linaclotide | 28 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | 13 |
| Nitroglycerin | Nitroglycerin | 28 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 26 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Mupirocin | Mupirocin | 21 | 13 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 20 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | suppressed |
| Cyclosporine | Cyclosporine | 19 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | 11 |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 14 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 14 | 12 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Calcipotriene | Calcipotriene | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Hydrocortisone-Acetic Acid | Hydrocortisone/Acetic Acid | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13,873.48 · 231 records | Amgen Inc. | ABRYSVO, ACCRUFER, AIRSUPRA, APTIMA, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EUFLEXXA, EVENITY, FARXIGA, FREESTYLE LIBRE, GARDASIL 9, GEMTESA, Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor, ImmunoCAP, JARDIANCE, JOURNAVX, KRYSTEXXA, Kerendia, LINZESS, M-M-R II, MAVYRET, MOUNJARO, NEXPLANON, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, PYRUKYND, QULIPTA, REPATHA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, Vemlidy, Veozah, Wegovy, XIFAXAN, XT CDX, YUPELRI, ZEPBOUND, ZORYVE, ZTLido | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error